Data for the treatment of triple-negative breast cancer (TNBC) were rather limited during SABCS 2024. The general sessions did feature two studies evaluating the addition of immune checkpoint inhibition to neoadjuvant chemotherapy in patients with newly diagnosed stage II or III TNBC. Both studies showed improved rates of pathological complete response (pCR) with the addition of immune checkpoint inhibition. In addition, two exploratory analyses of the KEYNOTE-522 trial were presented. In the advanced setting, the prophylactic use of granulocyte-colony stimulating factor (G-CSF) and loperamide was assessed in patients who received treatment with sacituzumab govitecan.